Stay updated with breaking news from Insightsnet Present Value Model. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dalzanemdor is a small molecule commercialized by Sage Therapeutics, with a leading Phase III program in Huntington Disease.
Dalzanemdor is a small molecule commercialized by Sage Therapeutics, with a leading Phase III program in Huntington Disease.
Laronidase is a recombinant enzyme commercialized by JCR Pharmaceuticals, with a leading Phase II program in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ).
Barzolvolimab is a monoclonal antibody commercialized by Celldex Therapeutics, with a leading Phase II program in Eosinophilic Esophagitis.
Linavonkibart is a monoclonal antibody commercialized by Scholar Rock Holding, with a leading Phase I program in Non-Small Cell Lung Cancer.